Full Doc
 | 2004 |
Avatar Reports 2003 Results
Avatar Reports 2003 Results (8K)
Doc #264811: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}e17203ex99_1.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
Exhibit 99.1
Avatar Reports 2003 Results
CORAL GABLES, Fla., March 11 /PRNewswire-FirstCall/ -- Avatar Holdings
Inc. (Nasdaq: AVTR) today reported net income for 2003 of $18,463,000 on
revenues of $253,008,000, compared with net income for 2002 of $5,627,000 on
revenues of $190,251,000.
Net income of $18,463,000 includes a tax benefit of $8,554,000 resulting
from a tax credit of $8,639,000 as the result of the elimination of certain
income tax reserves, a tax credit of $4,000,000 as a result of a reduction to
the valuation allowance for deferred income taxes and income tax expenses of
$4,085,000. For the year ended December 31, 2003, pre-tax income from
operations was $9,909,000.
The following table summarizes selected primary and active adult
homebuilding data for 2003, 2002 and 2001.
Closings 2003 2002 2001
Number of Units 1,193 926 764
Aggregate Dollar Volume $223,991,000 $160,354,000 $117,213,000
Average Price Per Unit $187,800 $173,200 $153,400
Contracts Signed
Number of Units 1,758 1,201 909
Aggregate Dollar Volume $349,371,000 $219,011,000 $153,442,000
Average Price Per Unit $198,700 $182,400 $168,800
Backlog
Number of Units 1,378 813 538
Aggregate Dollar Value $291,766,000 $166,386,000 $107,729,000
Average Price Per Unit $211,700 $204,700 $200,200
Sales for 2003 include 503 contracts for single-family homes at Solivita,
Avatar's Central Florida active adult community, 792 contracts for single-
family homes at the Central Florida community of Poinciana, 331 contracts for
single-family homes at Bellalago, adjacent to Poinciana, 31 contracts for
single-family homes at Cory Lake Isles in Tampa, Florida, 74 contracts for
single-family homes at Rio Rico, Arizona, and 27 contracts for single-family
homes at Harbor Islands in Hollywood, Florida.
At Harbor Islands 20 units remained for sale as of December 31, 2003,
which Avatar anticipates will be sold during 2004. Avatar anticipates that
closings of all units at Harbor Islands will be completed during 2005.
Avatar is an equity partner in a joint venture for development and
construction of Ocean Palms, a 38-story, 240-unit highrise beachfront
condominium in Hollywood, Florida, and sales are not included in the foregoing
chart. As of December 31, 2003, 184 units were sold at an aggregate sales
volume of $142,193,000. In December 2003, the joint venture closed on a
$115,000,000 construction loan.
In 2003, Avatar closed on the sale to Wal-Mart Stores East, L.P. of a
26.09-acre site adjacent to the Poinciana Shopping Center for a 203,622
square-foot super store. In February 2003, Avatar closed on the sale of a
150-acre site to Lowe's Home Improvement Warehouse for a 1.3 million square-
foot regional distribution center in the Poinciana Industrial Park.
During 2003, Avatar acquired 907 acres adjacent to its Solivita community,
to be utilized for expansion of Solivita, and closed on an additional
acquisition of 606 acres of 2,372 acres under contract in Poinciana.
In 2003, Avatar called for redemption of its 7% Convertible Subordinated
Notes due 2005 at the redemption price of $1,020 per $1,000 principal amount
outstanding. The 7% Notes were convertible into common stock at a conversion
price of $31.80 per share, or 31,447 shares per $1,000 principal amount of the
7% Notes. Of the $94,429,000 principal amount outstanding, $63,300,000
principal amount were redeemed, and $31,129,000 principal amount were
converted into 978,866 shares of common stock. The redemption resulted in the
recording of a net pre-tax loss of $1,532,000 in the consolidated statements
of operations for 2003.
On December 30, 2003, Avatar entered into a three-year $100,000,000 line
of credit facility secured by real property currently consisting of Crescent
Lakes and Cypress Woods in Poinciana, Solivita, Bellalago, Cory Lake Isles and
Harbor Islands.
Avatar's assets at December 31, 2003 totaled $362,719,000, compared to
$386,067,000 at December 31, 2002. Stockholders' equity at December 31, 2003
was $263,649,000, compared to $221,592,000 at December 31, 2002.
At December 31, 2003, there were 9,389,772 shares of Avatar Common Stock
outstanding with a book value of $28.08 per share.
Avatar anticipates that its income from continuing operations before
income taxes in 2004 will substantially exceed 2003 results, assuming, among
other things, no events causing a general economic decline occur. Avatar also
anticipates that during 2004 it will consummate sales of commercial,
industrial and other land. Avatar expects that cash flow generated from these
sources and external borrowings will enable it to continue to acquire new
development opportunities, expand operations at its existing communities and
commence development of new projects on properties currently owned and to be
acquired.
Avatar Holdings Inc. is primarily engaged in real estate operations in
Florida and Arizona. Its principal real estate operations are conducted at
Poinciana, Solivita and Bellalago in central Florida near Orlando, Harbor
Islands on Florida's east coast, Cory Lake Isles in Tampa, Florida, and at Rio
Rico, south of Tucson, AZ. Avatar's common shares trade on The Nasdaq Stock
Market under the symbol AVTR.
Certain statements discussed herein constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause the actual results,
performance or achievements of results to differ materially from any future
results, performance or achievements expressed or implied by such forward-
looking statements. Such risks, uncertainties and other important factors
include, among others: the successful implementation of Avatar's business
strategy; shifts in demographic trends affecting demand for active adult
communities and other real estate; the level of immigration and in-migration
into the areas in which Avatar conducts real estate activities; international
(in particular Latin America), national and local economic conditions and
events, including employment levels, interest rates, consumer confidence, the
availability of mortgage financing and demand for new and existing housing;
access to future financing; geopolitical risks; competition; changes in, or
the failure or inability to comply with, government regulations; and other
factors as are described in Item 7 (Management's Discussion and Analysis of
Financial Condition and Results of Operations) of Avatar's Form 10-K.
AVATAR HOLDINGS INC. AND SUBSIDIARIES
Selected financial data for the years ended December 31, 2003 and 2002
(Dollars in thousands except per share data)
2003 2002
Revenues $253,008 $190,251
Income from continuing operations $9,909 $5,641
before income taxes
Income tax (expense) benefit $8,554 ($2,266)
Income from continuing operations $18,463 $3,375
264811
|
Avatar Holdings
As referenced in this Avatar Reports 2003 Results:
Avatar Holdings
– SEQUENCE}3
{FILENAME}e17203ex99_1.txt
{DESCRIPTION}PRESS RELEASE
{TEXT}
Exhibit 99.1
Avatar Reports 2003 Results
CORAL GABLES, Fla., March 11 /PRNewswire-FirstCall/ -- Avatar Holdings
Inc. (Nasdaq: AVTR) today reported net income for 2003 of $18,463,000 on
revenues of $253,008,000, compared with net
_____________
Avatar Holdings – new
development opportunities, expand operations at its existing communities and
commence development of new projects on properties currently owned and to be
acquired.
Avatar Holdings Inc. is primarily engaged in real estate operations in
Florida and Arizona. Its principal real estate operations are conducted at
Poinciana, Solivita and
_____________
AVATAR HOLDINGS – are described in Item 7 (Management's Discussion and Analysis of
Financial Condition and Results of Operations) of Avatar's Form 10-K.
AVATAR HOLDINGS INC. AND SUBSIDIARIES
Selected financial data for the years ended December 31, 2003 and 2002
(Dollars in thousands except per share data)
2003
_____________
Avatar Holdings – 64
Total assets $362,719 $386,067
Total stockholders' equity $263,649 $221,592
Stockholders' equity per share $28.08 $25.24
SOURCE Avatar Holdings Inc.
-0- 03/11/2004
/CONTACT: Juanita I. Kerrigan, Avatar Holdings Inc., +1-305-442-7000/
/Web site: http://www.avatarhomes.com/
(AVTR)
_____________
Avatar Holdings – 649 $221,592
Stockholders' equity per share $28.08 $25.24
SOURCE Avatar Holdings Inc.
-0- 03/11/2004
/CONTACT: Juanita I. Kerrigan, Avatar Holdings Inc., +1-305-442-7000/
/Web site: http://www.avatarhomes.com/
(AVTR)
CO: Avatar Holdings Inc.
ST: Florida
IN: CST RLT
SU: ERN
{/
_____________
dt 165680
| |
Preview
Full Doc
| 2004 |
Ashford Hospitality Trust Completes Second Portfolio Acquisition for $33.9 Million
Ashford Hospitality Trust Completes Second Portfolio Acquisition for $33.9 Million (6K)
Doc #265075: Click preview link for longer preview.
NEWS RELEASE
Contact:
Douglas Kessler
Tripp Sullivan
COO and Head of Acquisitions
Corporate Communications, Inc.
(972) 490-9600
(615) 254-3376
ASHFORD HOSPITALITY TRUST COMPLETES SECOND PORTFOLIO ACQUISITION FOR $33.9 MILLION
Transaction Highlights:
Acquired at 9.36 Trailing 12-Month EBITDA Multiple
Solidifies Strategic Relationship with One of the Premier Developers in the Hospitality Industry
Provides Substantial Diversification to Ashfords 15-Property Portfolio in Fast-Growing Markets
DALLAS (November 25, 2003) Ashford Hospitality Trust, Inc. (NYSE: AHT) today announced it has closed on the acquisition of a four-property, 393-room portfolio of hotels from Noble Investment Group for $33,850,000, or approximately $86,000 per key. The transaction is the second acquisition completed by the Company in as many months and increases its current portfolio to 15 hotel properties totaling 2,381 rooms.
The acquired portfolio consists of the following Hilton and Marriott branded hotels: the Hilton Garden Inn in Jacksonville, Florida; the SpringHill Suites by Marriott in Jacksonville, Florida; the Homewood Suites in Mobile, Alabama; and the Hampton Inn in Atlanta/Lawrenceville, Georgia. The Company purchased the four limited service hotels at a trailing 12-month EBITDA multiple of 9.36. Ashford intends to invest an additional $1.0 million of capital improvements into the newly built, high-quality hotels. Noble Management Group, a wholly owned management affiliate of Noble Investment Group, will continue to operate the four properties under incentive-based management agreements.
Diversification and flexibility are key tenets of Ashford Hospitality Trusts investment strategy, stated Monty J. Bennett, President and CEO. These four properties provide significant geographic, segment and service level diversification to our portfolio and are consistent with our focus on the elite hotel brands. Noble is an extremely qualified owner, developer and operator. This transaction cements a strategic relationship with one of the
265075
|
Ashford
As referenced in this Ashford Hospitality Trust Completes Second Portfolio Acquisition for $33.9 Million:
ASHFORD HOSPITALITY TRUST – 99.6
NEWS RELEASE
Contact:
Douglas Kessler
Tripp Sullivan
COO and Head of Acquisitions
Corporate Communications, Inc.
(972) 490-9600
(615) 254-3376
ASHFORD HOSPITALITY TRUST COMPLETES SECOND PORTFOLIO ACQUISITION FOR $33.9 MILLION
Transaction Highlights:
Acquired at 9.36 Trailing 12-Month EBITDA Multiple
Solidifies Strategic Relationship with
_____________
Ashford Hospitality Trust, – the Premier Developers in the Hospitality Industry
Provides Substantial Diversification to Ashfords 15-Property Portfolio in Fast-Growing Markets
DALLAS (November 25, 2003) Ashford Hospitality Trust, Inc. (NYSE: AHT) today announced it has closed on the acquisition of a four-property, 393-room portfolio of hotels from Noble
_____________
Ashford Hospitality Trust – office park, the six-year-old property also provides guests convenient access to one of Atlantas top shopping destinations the Mall of Georgia.
* * * * *
Ashford Hospitality Trust is a self-administered real estate investment trust focused exclusively on investing in the hospitality industry across all segments and at all levels
_____________
dt 165487
;
Douglas Kessler;
Tripp Sullivan;
| Corporate Communications, Inc.;
Noble Investment Group
|
Preview
Full Doc
| 2004 |
Apartment Investment and Management Company Announces Fourth Quarter 2003 Results
Apartment Investment and Management Company Announces Fourth Quarter 2003 Results (185K)
Doc #265296: Click preview link for longer preview.
AIMCO 4th Quarter 2003
Denver, Colorado?February 12, 2004
Apartment Investment and Management Company
Announces Fourth Quarter 2003 Results
SUMMARY FINANCIAL RESULTS Apartment Investment and Management Company ("Aimco") (NYSE:AIV) announced fourth quarter 2003 results including:
Net Income was $37.2 million, compared with $6.6 million in the fourth quarter 2002. Earnings (loss) per share (EPS) were $0.19 on a diluted basis, compared with $(0.17) in the same period last year, based on Net Income (loss) attributable to common stockholders.
Funds . . .
265296
|
Aimco Properties
As referenced in this Apartment Investment and Management Company Announces Fourth Quarter 2003 Results:
AIMCO Properties, L.P., – its presentation of the Consolidated Statements of Income pursuant to Rule 5-03 of Regulation S-X
[b]
The Aimco Operating Partnership is AIMCO Properties, L.P., the operating partnership in Aimco's UPREIT structure
1
[c]
Income from discontinued operations of consolidated properties is broken down as follows (
_____________
AIMCO Properties, L.P.) – charges for redemption related preferred stock issuance costs and impairment losses, all of which are adjusted for the Aimco operating partnership's share (AIMCO Properties, L.P.) . Similar to FFO, AFFO captures real estate performance by recognizing that real estate generally appreciates over time or maintains residual value to
_____________
dt 193997
;
AIMCO
As referenced in this Apartment Investment and Management Company Announces Fourth Quarter 2003 Results:
Apartment Investment and Management – EX 99.1
QuickLinks -- Click here to rapidly navigate through this document
Exhibit 99.1
AIMCO 4th Quarter 2003
Denver, ColoradoFebruary 12, 2004
Apartment Investment and Management Company
Announces Fourth Quarter 2003 Results
SUMMARY FINANCIAL RESULTS Apartment Investment and Management Company ("Aimco") (NYSE:AIV) announced fourth quarter 2003 results including:
_____________
Apartment Investment and Management – 99.1
AIMCO 4th Quarter 2003
Denver, ColoradoFebruary 12, 2004
Apartment Investment and Management Company
Announces Fourth Quarter 2003 Results
SUMMARY FINANCIAL RESULTS Apartment Investment and Management Company ("Aimco") (NYSE:AIV) announced fourth quarter 2003 results including:
Net Income was $37.2 million, compared with $6.6 million in the
_____________
Apartment Investment and Management – 0.83
$
2.59
$
3.77
Contact: Investor Relations 303.691.4350, Investor@Aimco.com
Jennifer Martin, Vice PresidentInvestor Relations 303.691.4440
Apartment Investment and Management Company
Fourth Quarter 2003Page 2
Full year 2003 FFO results include charges of $7.6 million in issuance costs associated with preferred share
_____________
Apartment Investment and Management – of Tom Herzog from GE Real Estate to serve as Chief Accounting Officer; and by active portfolio management, selling weaker properties in weaker
Apartment Investment and Management Company
Fourth Quarter 2003Page 3
markets to invest in such better assets as The Palazzo, in the mid-Wilshire district of Los Angeles."
_____________
Apartment Investment and Management – Same Store" portfolio net operating income was $170.0 million for the fourth quarter 2003, down 8.1% from the fourth quarter 2002.
Apartment Investment and Management Company
Fourth Quarter 2003Page 4
SAME STORE OPERATING RESULTS
Fourth Quarter
Sequential
2003
2002
Variance
3rd Qtr 03
Variance
Same Store Operating Measures:
_____________
dt 152458
;
|
Casden
As referenced in this Apartment Investment and Management Company Announces Fourth Quarter 2003 Results:
Casden Properties – on its revolving credit facility, and $104 remaining outstanding on the term loan entered into in connection with the March 2002 acquisition of Casden Properties Inc.
Total proportionate debt decreased by $299 million during the quarter including: (i) $79 million reduction on the revolving credit facility; (ii) $260
_____________
dt 230044
|
| Full Doc
| 2004 |
Homestore Reports Fourth Quarter and Full Year 2003 Results
Homestore Reports Fourth Quarter and Full Year 2003 Results (34K)
Doc #267986: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}v97315exv99w1.txt
{DESCRIPTION}EXHIBIT 99.1
{TEXT}
{PAGE}
Exhibit 99.1
HOMESTORE REPORTS FOURTH QUARTER AND FULL YEAR 2003
RESULTS
Reduced Operating Losses, Improved Gross Margins
WESTLAKE VILLAGE, CALIF. - MARCH 11, 2003 - Homestore, Inc. (NASDAQ: HOMS), the
leading provider of real estate media and technology solutions, today reported
financial results for the fourth quarter ended December 31, 2003. Total revenue
for the fourth quarter was $54.9 million, compared to $55.1 million in the third
quarter of 2003. The gross margin improved to 74 percent from 72 percent in the
previous quarter.
Homestore also reported that the net loss for the fourth quarter was $(12.1)
million, or $(0.10) per share, compared to a net loss of $(30.6) million, or
$(0.26) per share, for the third quarter of 2003. Results for the fourth quarter
included a restructuring charge of $4.1 million and an impairment charge of $1.8
million. The third quarter results included an impairment charge of $15.7
million. Excluding restructuring, impairment and certain other non-cash
expenses, principally stock-based charges, depreciation, and amortization,
Homestore's loss from operations was $(770,000) in the fourth quarter, compared
to a loss of $(4.8) million in the third quarter of 2003. The decrease in loss
was primarily due to reductions in the Company's operating expenses. This
information is provided because management uses it to monitor and assess the
Company's performance and believes it is helpful to investors in understanding
the Company's business.
At December 31, 2003, Homestore had $35.5 million in cash and short-term
investments available to fund operations. This cash balance reflects a $10.0
million payment made on October 15, 2003, related to the class action
settlement.
"As we move beyond the historical financial, legal and operational issues that
challenged the Company's development, we are encouraged by the returns we are
receiving from our staged product and marketing investment priorities," said
Mike Long, Homestore's chief executive officer. "Homestore's Media Services
segment, our largest business and the primary beneficiary of our investment
strategy to date, experienced its third consecutive quarter of sequential core
revenue growth. This segment also achieved improved profitability, with
operating margins increasing from 6.6 percent in the third quarter to 15 percent
in the fourth. We believe these
{PAGE}
trends are early indicators of the market acceptance of our products and
services, better reflecting the value we deliver to our customers."
YEAR OVER YEAR QUARTERLY RESULTS
Revenue for the fourth quarter totaled $54.9 million, versus $60.8 million for
the fourth quarter of 2002. The year over year decline in revenue is due
primarily to the expiration of certain legacy revenue agreements with Cendant
Corp., which accounted for $3.6 million, and a decline in software revenues from
the sale of The Hessel Group in early 2003.
The loss from continuing operations was $(12.1) million, or $(0.10) per share,
compared to a loss of $(37.6) million, or $(0.32) per share, in the fourth
quarter of 2002. The net loss for the fourth quarter was $(12.1) million, or
$(0.10) per share, compared to a net loss of $(36.6) million, or $(0.31) per
share, in the fourth quarter of 2002.
FULL YEAR RESULTS
For the year ended December 31, 2003, Homestore's revenue was $218.7 million,
down $45.9 million from revenue of $264.6 million for 2002. The loss from
continuing operations was $(49.7) million, or $(0.42) per share, compared to
$(176.1) million, or $(1.49) per share for 2002. The net loss for the year was
$(47.1) million, or $(0.40) per share, compared with a net loss of $(163.4)
million, or $(1.39) per share, for the year ended December 31, 2002.
UPDATE ON SETTLEMENT OF SHAREHOLDER CLASS ACTION LAWSUIT
Last October, Homestore announced a preliminary court approval of the settlement
agreement between Homestore and The California State Teachers' Retirement System
(CalSTRS) related to the consolidated shareholder class action lawsuit. A final
court approval hearing took place on January 16, 2004. Thereafter, the court
issued an interim order in which the judge generally approved of the terms of
the settlement but requested additional briefing from the parties on ancillary
issues. The briefs were submitted February 20, 2004, and Homestore expects a
decision regarding trial court approval of the settlement in the near future.
Under the terms of the settlement, Homestore has agreed to pay $13.0 million in
cash and issue 20.0 million new shares of Homestore common stock to members of
the class and will adopt certain corporate governance provisions designed to
enhance shareholder interests. Homestore has already transferred $10 million in
cash into an escrow account during the fourth quarter, with
{PAGE}
the additional $3.0 million in cash and 20.0 million shares of common stock due
upon final judicial approval of the settlement. Following the final approval,
the $13.0 million, net of court approved costs, and the 20.0 million shares of
newly issued common stock will be distributed to the class. Additional
information regarding the settlement agreement is included in documents
Homestore files from time to time with the Securities and Exchange Commission.
CONFERENCE CALL
As previously announced, Homestore will host a conference call, which will be
broadcast live over the Internet today, Thursday, March 11, 2004, at 2:00 p.m.
PST (5:00 p.m. EST). Chief Executive Officer, Mike Long, and Chief Financial
Officer, Lew Belote, will discuss the Company's fourth quarter and full year
2003 results, and Homestore's progress. In order to participate in the call,
investors should log on to http://ir.homestore.com and click on "Event
Calendar." Windows Media Player software is required and is obtainable at no
cost. Please connect to the above Web site ten minutes prior to the call to load
any necessary audio software. A replay of the call will be available in the same
section of the Company's Web site. A telephone replay will also be available
from 5:00 p.m. PDT (8:00 p.m. EDT) on March 11 until midnight on March 18 at
706-645-9291, conference code 5616994. For additional information regarding the
company's results, please go to the "SEC Filings" section at
http://ir.homestore.com to view annual reports as filed with the Securities and
Exchange Commission on Form 10-K. Homestore's Form 10-K for the year ended
December 31, 2003 is expected to be filed with the Securities and Exchange
Commission on, or before Monday, March 15, 2004.
USE OF NON-GAAP FINANCIAL MEASURES
To supplement its consolidated financial statements presented in accordance with
generally accepted accounting principles in the United States ("GAAP"),
Homestore uses a non-GAAP measure of income (loss) from operations excluding
restructuring, impairment and certain other non-cash expenses. A reconciliation
of this non-GAAP measure to GAAP is provided in the attached tables. These
non-GAAP adjustments are provided to enhance the user's overall understanding of
Homestore's current financial performance and its prospects for the future.
Homestore believes these non-GAAP results provide useful information to both
management and investors by excluding certain expenses that it believes are not
indicative of its core operating results and a more consistent basis for
comparison between quarters. Further, this non-GAAP method is the primary basis
management uses for planning and forecasting its future operations. The
presentation of this additional information should not be considered in
isolation or as a substitute for results prepared in accordance with GAAP.
267986
|
Cendant
As referenced in this Homestore Reports Fourth Quarter and Full Year 2003 Results:
Cendant
Corp – fourth quarter of 2002. The year over year decline in revenue is due
primarily to the expiration of certain legacy revenue agreements with Cendant
Corp ., which accounted for $3.6 million, and a decline in software revenues from
the sale of The Hessel Group in early 2003.
_____________
dt 278082
;
Homestore
As referenced in this Homestore Reports Fourth Quarter and Full Year 2003 Results:
HOMESTORE – {DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}v97315exv99w1.txt
{DESCRIPTION}EXHIBIT 99.1
{TEXT}
{PAGE}
Exhibit 99.1
HOMESTORE REPORTS FOURTH QUARTER AND FULL YEAR 2003
RESULTS
Reduced Operating Losses, Improved Gross Margins
WESTLAKE VILLAGE, CALIF. - MARCH 11, 2003 - Homestore, Inc. (NASDAQ:
_____________
Homestore, – 99.1
HOMESTORE REPORTS FOURTH QUARTER AND FULL YEAR 2003
RESULTS
Reduced Operating Losses, Improved Gross Margins
WESTLAKE VILLAGE, CALIF. - MARCH 11, 2003 - Homestore, Inc. (NASDAQ: HOMS), the
leading provider of real estate media and technology solutions, today reported
financial results for the fourth quarter ended
_____________
Homestore – 55.1 million in the third
quarter of 2003. The gross margin improved to 74 percent from 72 percent in the
previous quarter.
Homestore also reported that the net loss for the fourth quarter was $(12.1)
million, or $(0.10) per share, compared to a net
_____________
Homestore' – an impairment charge of $15.7
million. Excluding restructuring, impairment and certain other non-cash
expenses, principally stock-based charges, depreciation, and amortization,
Homestore' s loss from operations was $(770,000) in the fourth quarter, compared
to a loss of $(4.8) million in the third quarter
_____________
Homestore – and assess the
Company's performance and believes it is helpful to investors in understanding
the Company's business.
At December 31, 2003, Homestore had $35.5 million in cash and short-term
investments available to fund operations. This cash balance reflects a $10.0
million payment
_____________
dt 175873
;
| |
Preview
Full Doc
| 2004 |
HRPT Properties Trust Announces Financial Results for the Periods Ended December 31, 2003
HRPT Properties Trust Announces Financial Results for the Periods Ended December 31, 2003 (21K)
Doc #268601: Click preview link for longer preview.
FOR IMMEDIATE RELEASE
Contact:
John C. Popeo, Treasurer
(617) 332-3990
www.hrpreit.com
HRPT Properties Trust
Announces Financial Results for the
Periods Ended December 31, 2003
Newton, MA (February 11, 2004): HRPT Properties Trust (NYSE: HRP) today announced its financial results for the periods ended December 31, 2003, together with comparative results for the 2002 periods as follows:
(in thousands, except per share data)
. . .
268601
|
CUI
As referenced in this HRPT Properties Trust Announces Financial Results for the Periods Ended December 31, 2003:
Collectors Universe, Inc – SVS, Inc.
11/07/03
St. Louis, MO
1
67
8,950
MetLife
11/10/03
Santa Ana, CA
1
68
13,550
Collectors Universe, Inc .
12/05/03
Oahu, HI
11
9,755
480,000
Safeway Inc.
12/19/03
Tolleson, AZ
1
236
12,500
Duro
_____________
dt 268285
;
HRPT Properties
As referenced in this HRPT Properties Trust Announces Financial Results for the Periods Ended December 31, 2003:
HRPT Properties Trust
– a04-2235_1ex99d1.htm EX-99.1
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact:
John C. Popeo, Treasurer
(617) 332-3990
www.hrpreit.com
HRPT Properties Trust
Announces Financial Results for the
Periods Ended December 31, 2003
Newton, MA (February 11, 2004): HRPT Properties Trust (NYSE: HRP) today announced
_____________
HRPT Properties Trust – 332-3990
www.hrpreit.com
HRPT Properties Trust
Announces Financial Results for the
Periods Ended December 31, 2003
Newton, MA (February 11, 2004): HRPT Properties Trust (NYSE: HRP) today announced its financial results for the periods ended December 31, 2003, together with comparative results for the 2002 periods
_____________
HRPT Properties Trust – distributions paid
$
0.20
$
0.20
$
0.80
$
0.80
Weighted average common shares outstanding
142,774
128,825
136,270
128,817
HRPT Properties Trust is a real estate investment trust headquartered in Newton, MA.
(end)
1
HRPT Properties Trust
Statement of Income and Funds From Operations
(in
_____________
HRPT Properties Trust
– 142,774
128,825
136,270
128,817
HRPT Properties Trust is a real estate investment trust headquartered in Newton, MA.
(end)
1
HRPT Properties Trust
Statement of Income and Funds From Operations
(in thousands, except per share data)
Quarter Ended December 31,
Year Ended December 31,
2003
_____________
HRPT Properties Trust
– bank credit facility and public debt covenants, the availability of debt and equity capital to us and our expectation of future performance.
2
HRPT Properties Trust
Balance Sheet
(dollars in thousands)
December 31,
2003
2002
Assets
Real estate properties, at cost
$
3,891,966
$
3,074,656
Accumulated
_____________
dt 176487
;
|
Safeway
As referenced in this HRPT Properties Trust Announces Financial Results for the Periods Ended December 31, 2003:
Safeway Inc – 11/10/03
Santa Ana, CA
1
68
13,550
Collectors Universe, Inc.
12/05/03
Oahu, HI
11
9,755
480,000
Safeway Inc .
12/19/03
Tolleson, AZ
1
236
12,500
Duro Standard Products
27
12,672
$
795,417
(1) Excludes closing costs.
9
_____________
dt 178244
;
 Ballard Spahr
As referenced in this HRPT Properties Trust Announces Financial Results for the Periods Ended December 31, 2003:
Ballard Spahr – 9.1
1.7
%
Solectron Corporation
8.9
1.6
%
Motorola, Inc.
8.6
1.5
%
Mellon Financial Corporation
7.5
1.4
%
Ballard Spahr Andrews & Ingersoll, LLP
7.4
1.4
%
FMC Corporation
7.4
1.4
%
Fallon Clinics
7.2
1.3
%
Comcast Corporation
6.
_____________
dt 168416
|
Preview
Full Doc
| 2004 |
Innkeepers USA Trust Announces Fourth Quarter and Year 2003 Earnings
Innkeepers USA Trust Announces Fourth Quarter and Year 2003 Earnings (46K)
Doc #269049: Click preview link for longer preview.
For Immediate Release
Contact:
David Bulger (Company)
CFO, Treasurer and EVP
(561) 227-1302
Jerry Daly or Carol McCune
Daly Gray (Media)
(703) 435-6293
Innkeepers USA Trust Announces Fourth Quarter and Year 2003 Earnings
PALM BEACH, Fla., February 3, 2003?Innkeepers USA Trust (NYSE: KPA), a hotel real estate investment trust (REIT) and a leading owner of upscale, extended-stay hotel properties throughout the United States, today announced results for the fourth quarter and the year 2003.
. . .
269049
|
Innkeepers USA
As referenced in this Innkeepers USA Trust Announces Fourth Quarter and Year 2003 Earnings:
Innkeepers USA Trust – Release
Contact:
David Bulger (Company)
CFO, Treasurer and EVP
(561) 227-1302
Jerry Daly or Carol McCune
Daly Gray (Media)
(703) 435-6293
Innkeepers USA Trust Announces Fourth Quarter and Year 2003 Earnings
PALM BEACH, Fla., February 3, 2003Innkeepers USA Trust (NYSE: KPA), a hotel real estate investment trust (
_____________
Innkeepers USA Trust – a litigation settlement. The other charges in 2002 related to the TRS transaction ($149,000) and a litigation settlement ($3,318,000).
- more -
Innkeepers USA Trust
Page 2
Highlights
The company announced a taxable REIT subsidiary (TRS) transaction to purchase 60 hotel property leases from Innkeepers Hospitality. As
_____________
Innkeepers USA Trust – of credit facility, which matures in July 2004.
The company sold the 126-suite Residence Inn in Minneapolis, Minnesota in January 2004.
- more -
Innkeepers USA Trust
Page 3
RevPAR Results
RevPAR for the companys 66 comparable hotel properties declined 0.9 percent for the fourth quarter 2003 to $
_____________
Innkeepers USA Trust – officer and president. Since 2000, we have witnessed a series of national and global events that severely impacted lodging demand. In 2001,
- more -
Innkeepers USA Trust
Page 4
we experienced economic softening, which was exacerbated by the events of September 11. In 2002, there were concerns about the
_____________
Innkeepers USA Trust – 4,400
$
0.11
$
13,600
$
(3,700
)
$
(0.10
)
Full year
$
22,900
$
0.59
$
63,900
$
(9,700
)
$
(0.26
)
- more -
Innkeepers USA Trust
Page 5
The forecasted financial results above include the effects of the following:
The write-off of $4,248,000 for the
_____________
dt 176906
| |
Preview
Full Doc
| 2004 |
Aquantive, Inc. Announces 2003 Fourth Quarter Results
Aquantive, Inc. Announces 2003 Fourth Quarter Results (12K)
Doc #273911: Click preview link for longer preview.
aQuantive, Inc.
206.816.8700 // tel
506 Second Avenue
206.816.8808 // fax
Seattle, WA 98104
aquantive.com // web
For immediate release on Thursday, January 29th at 12:01 PST/3:01am EST
Contacts:
Investor Relations
Public Relations
Angy Merola
Angela Gamba
aQuantive, Inc.
aQuantive, Inc
(206) 816-8334
(206) 816-8245
. . .
273911
|
aQuantive
As referenced in this Aquantive, Inc. Announces 2003 Fourth Quarter Results:
aQuantive, –
PRESS RELEASE
EX-99.1 3 dex991.htm PRESS RELEASE
Exhibit 99.1
aQuantive, Inc.
206.816.8700 // tel
506 Second Avenue
206.816.8808 // fax
Seattle, WA 98104
aquantive.com // web
For immediate release on
_____________
aquantive. – dex991.htm PRESS RELEASE
Exhibit 99.1
aQuantive, Inc.
206.816.8700 // tel
506 Second Avenue
206.816.8808 // fax
Seattle, WA 98104
aquantive. com // web
For immediate release on Thursday, January 29th at 12:01 PST/3:01am EST
Contacts:
Investor Relations
Public Relations
Angy Merola
_____________
aQuantive, – For immediate release on Thursday, January 29th at 12:01 PST/3:01am EST
Contacts:
Investor Relations
Public Relations
Angy Merola
Angela Gamba
aQuantive, Inc.
aQuantive, Inc
(206) 816-8334
(206) 816-8245
Conference Call and Webcast at 8am PST/11am EST Today
AQUANTIVE, INC. ANNOUNCES
_____________
aQuantive, – release on Thursday, January 29th at 12:01 PST/3:01am EST
Contacts:
Investor Relations
Public Relations
Angy Merola
Angela Gamba
aQuantive, Inc.
aQuantive, Inc
(206) 816-8334
(206) 816-8245
Conference Call and Webcast at 8am PST/11am EST Today
AQUANTIVE, INC. ANNOUNCES 2003 FOURTH
_____________
AQUANTIVE, – Merola
Angela Gamba
aQuantive, Inc.
aQuantive, Inc
(206) 816-8334
(206) 816-8245
Conference Call and Webcast at 8am PST/11am EST Today
AQUANTIVE, INC. ANNOUNCES 2003 FOURTH QUARTER RESULTS
Strong 2003 Ends on High Note with 135 Percent Increase in Q4 Net Income and a
_____________
dt 182002
| |
| Full Doc
| 2004 |
MacroChem Announces $7.29 Million Private Placement with Institutional Investors
MacroChem Announces $7.29 Million Private Placement with Institutional Investors (4K)
Doc #274643: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99
{SEQUENCE}6
{FILENAME}pressrelease031004.txt
{DESCRIPTION}PRESS RELEASE OF 03-10-04
{TEXT}
EXHIBIT 99.1
------------
Release: IMMEDIATE Contact: Bernard Patriacca - VP/CFO
(781) 862-4003
MACROCHEM ANNOUNCES $7.29 MILLION PRIVATE PLACEMENT WITH INSTITUTIONAL INVESTORS
Lexington, MA, March 10, 2003 -- MacroChem Corporation (Nasdaq: MCHM),
announced today that it has raised approximately $7.29 million in gross proceeds
from a private placement of its securities to institutional investors.
In this private placement, MacroChem issued 5,402,000 shares of common
stock, at a per share purchase price of $1.35. The investors also received
five-year warrants to purchase 1,080,400 shares of the company's common stock at
an exercise price of $2.09 per share. The company has agreed to file a
registration statement on Form S-3 covering the resale of the common stock sold
and the shares issuable upon exercise of the warrants.
JMP Securities LLC, a San Francisco based investment banking firm and
advisor to MacroChem, acted as placement agent in connection with this
transaction.
The securities sold in the private placement have not been registered under
the Securities Act of 1933, as amended (the "Securities Act"), and may not be
offered or sold in the United States unless registered under the Securities Act
or an applicable exemption from registration is available. This press release
does not constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state.
About MacroChem Corp.
MacroChem is a specialty pharmaceutical company that innovates, develops
and commercializes pharmaceuticals administered in novel ways, to treat
important medical conditions. MacroChem is developing three products containing
its patented drug-absorption enhancer, SEPA(R): Topiglan(R), a SEPA-enhanced
synthetic prostaglandin E1, for erectile dysfunction; Opterone(TM), a
SEPA-enhanced topical treatment for men with testosterone deficiency; and
EcoNail(TM), a SEPA-enhanced antifungal nail lacquer to treat a common and
potentially debilitating nail infection known as onychomycosis. For further
information please consult http://www.macrochem.com
-more-
{PAGE}
Page 2
About JMP Securities
Established in 2000, JMP Securities is a full-service investment bank
helping growth companies and their investors. A top-25 lead-manager of equity
underwritings, San Francisco-based JMP has more than 115 experienced
professionals (38 partners) who provide services in equity research, investment
banking and sales and trading. JMP focuses on the following growth sectors of
the economy: business services, consumer, financial services, healthcare and
technology. For more information, visit www.jmpsecurities.com
-end-
WITH THE EXCEPTION OF HISTORICAL INFORMATION CONTAINED IN THIS PRESS RELEASE,
THE MATTERS DESCRIBED HEREIN ARE FORWARD-LOOKING STATEMENTS AND ARE SUBJECT TO
VARIOUS RISK FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM
THOSE EXPRESSED IN THE FORWARD-LOOKING STATEMENTS. THE RELEVANT RISK FACTORS ARE
SET FORTH IN MACROCHEM'S ANNUAL REPORT ON FORM 10-K AS FILED WITH THE SEC AND
INCLUDE, WITHOUT LIMITATION, RISKS REGARDING PRODUCT DEVELOPMENT, CLINICAL
TRIALS, CAPITAL REQUIREMENTS, FINANCIAL CONDITION, DEPENDENCE ON THIRD PARTIES
FOR DEVELOPMENT AND LICENSING ARRANGEMENTS, AND RISKS INVOLVING REGULATORY
APPROVAL OF PRODUCTS, AND PATENTS AND LICENSES.
Visit our web site at: http://www.macrochem.com
{/TEXT}
{/DOCUMENT}
274643
|
MacroChem
As referenced in this MacroChem Announces $7.29 Million Private Placement with Institutional Investors:
MacroChem Corp – Contact: Bernard Patriacca - VP/CFO
(781) 862-4003
MACROCHEM ANNOUNCES $7.29 MILLION PRIVATE PLACEMENT WITH INSTITUTIONAL INVESTORS
Lexington, MA, March 10, 2003 -- MacroChem Corp oration (Nasdaq: MCHM),
announced today that it has raised approximately $7.29 million in gross proceeds
from a private placement of its securities
_____________
MacroChem Corp – such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state.
About MacroChem Corp .
MacroChem is a specialty pharmaceutical company that innovates, develops
and commercializes pharmaceuticals administered in novel ways, to treat
important medical conditions. MacroChem
_____________
dt 192782
;
|
 JMP Securities
As referenced in this MacroChem Announces $7.29 Million Private Placement with Institutional Investors:
JMP Securities LLC – registration statement on Form S-3 covering the resale of the common stock sold
and the shares issuable upon exercise of the warrants.
JMP Securities LLC , a San Francisco based investment banking firm and
advisor to MacroChem, acted as placement agent in connection with this
transaction.
The securities
_____________
dt 197225
|
| Full Doc
| 2004 |
Lorus Therapeutics Inc. Publishes Preclincal Results Describing NC 381, A Lung Cancer Anti-Tumor Agent
Lorus Therapeutics Inc. Publishes Preclincal Results Describing NC 381, A Lung Cancer Anti-Tumor Agent (6K)
Doc #279427: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}t12179exv99w1.txt
{DESCRIPTION}EX-99.1
{TEXT}
{PAGE}
.
.
.
Exhibit 99.1
CONTACTS:
{TABLE}
{S} {C} {C}
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
{/TABLE}
LORUS THERAPEUTICS INC. PUBLISHES PRECLINCAL RESULTS DESCRIBING NC 381,
A LUNG CANCER ANTI-TUMOR AGENT
- Novel derivative of an anti-fungal drug with anti-tumor properties--
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, DECEMBER 1, 2003 - Scientists at Lorus Therapeutics Inc.
("Lorus") have published the results of investigations aimed at characterizing a
clotrimazole (CLT) analogue, NC 381. CLT is an anti-fungal drug that has
demonstrated anti-cancer activity but its potential is limited by the presence
of high liver toxicity. The goal of the study was to develop a variation or
analogue of CLT that maintained the anti-cancer activity without the toxic side
effects. The results appear in an article entitled, "NC 381, A Novel Anti-cancer
Agent, Arrests the Cell Cycle in G0-G1 and Inhibits Lung Tumor Cell Growth In
Vitro and In Vivo" in a November electronic version of the Journal of
Pharmacology and Experimental Therapeutics. The article will also be published
in print in an upcoming issue of the journal.
The article explained that when a chemical component of CLT responsible for
toxicity was removed in designing the analogue NC 381, the new drug inhibited
the growth of cancer cells in vitro by a mechanism of action that was similar to
CLT. Therefore, this new drug appears to be a safer agent that maintains
anti-cancer activity.
Also, the clinical applicability of NC 381 was evaluated in a mouse model of
human lung cancer. In this model, NC 381 treatment significantly inhibited tumor
growth in vivo, demonstrating the potential of NC 381 for treatment of lung
cancer.
(more)
{PAGE}
Lorus recently licensed NC 381 and the library of CLT analogs to Cyclacel
Limited ("Cyclacel"), a UK-based biopharmaceutical company. Lorus received an
upfront payment for the library including NC 381, and assuming all clinical
development milestones are achieved by Cyclacel, Lorus will also receive
milestone payments that total approximately US $11.6 million for NC 381 and for
each of any other compounds developed from the compound library. In addition to
these payments, Lorus will receive royalties based on product sales.
"Cyclacel has expertise in the area of drug development represented by
anti-cancer agents like NC 381 and the other CLT analogs, and is an excellent
partner for Lorus," said Dr. Jim Wright, CEO of Lorus. "This agreement is also
consistent with Lorus' focus on progressing its strong preclinical and clinical
programs that are now underway and showing very promising results."
About Lorus
Lorus is a biopharmaceutical company focused on the research and development of
cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical,
clinical and regulatory expertise by developing new drug candidates that can be
used, either alone, or in combination, to successfully manage cancer. Through
its own discovery efforts and an active acquisition and in-licensing program,
Lorus is building a portfolio of promising anti-cancer drugs. Late-stage
clinical developments and marketing will be done in cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on the
OTC BB exchange under the symbol LORFF.
Forward Looking Statements
Except for historical information, this press release contains forward-looking
statements, which reflect the Company's current expectation and assumptions, and
are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated. These forward-looking
statements involve risks and uncertainties, including, but not limited to,
changing market conditions, the Company's ability to obtain patent protection
and protect its intellectual property rights, commercialization limitations
imposed by intellectual property rights owned or controlled by third parties,
intellectual property liability rights and liability claims asserted against the
Company, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, product development delays, the Company's ability to attract
and retain business partners and key personnel, future levels of government
funding, the Company's ability to obtain the capital required for research,
operations and marketing and other risks detailed from time-to-time in the
Company's ongoing quarterly filings, annual information form, annual reports and
20-F filings. We undertake no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's
Internet site: http://www.lorusthera.com.
-30-
{/TEXT}
{/DOCUMENT}
279427
|
Lorus
As referenced in this Lorus Therapeutics Inc. Publishes Preclincal Results Describing NC 381, A Lung Cancer Anti-Tumor Agent:
LORUS THERAPEUTICS – TYPE}EX-99.1
{SEQUENCE}3
{FILENAME}t12179exv99w1.txt
{DESCRIPTION}EX-99.1
{TEXT}
{PAGE}
.
.
.
Exhibit 99.1
CONTACTS:
{TABLE}
{S} {C} {C}
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416)
_____________
LORUS THERAPEUTICS – ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
{/TABLE}
LORUS THERAPEUTICS INC. PUBLISHES PRECLINCAL RESULTS DESCRIBING NC 381,
A LUNG CANCER ANTI-TUMOR AGENT
- Novel derivative of an anti-fungal drug with anti-tumor
_____________
Lorus Therapeutics – Novel derivative of an anti-fungal drug with anti-tumor properties--
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, DECEMBER 1, 2003 - Scientists at Lorus Therapeutics Inc.
("Lorus") have published the results of investigations aimed at characterizing a
clotrimazole (CLT) analogue, NC 381. CLT is an anti-fungal drug
_____________
Lorus Therapeutics – of promising anti-cancer drugs. Late-stage
clinical developments and marketing will be done in cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on the
OTC BB exchange under the
_____________
Lorus Therapeutics – undertake no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's
Internet site: http://www.lorusthera.com.
-30-
{/TEXT}
{/DOCUMENT}
_____________
dt 211243
| |
| Full Doc
| 2004 |
Lorus Therapeutics Inc. Publishes Results of Synthesis and Characterization of Clotrimazole Analogues as Anticancer Agents
Lorus Therapeutics Inc. Publishes Results of Synthesis and Characterization of Clotrimazole Analogues as Anticancer Agents (5K)
Doc #279428: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99.2
{SEQUENCE}4
{FILENAME}t12179exv99w2.txt
{DESCRIPTION}EX-99.2
{TEXT}
{PAGE}
.
.
.
Exhibit 99.2
CONTACTS:
{TABLE}
{S} {C} {C}
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
{/TABLE}
LORUS THERAPEUTICS INC. PUBLISHES RESULTS OF SYNTHESIS AND
CHARACTERIZATION OF CLOTRIMAZOLE ANALOGUES AS ANTICANCER AGENTS
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, DECEMBER 15, 2003 - Scientists at Lorus Therapeutics Inc.
("Lorus") have published the results of experimental studies aimed at
synthesizing and optimizing analogues of clotrimazole (CLT), an anti-fungal drug
that has demonstrated anticancer activity. These studies were part of a larger
project that characterized NC 381, a CLT derivative that was extensively studied
as a lead drug candidate. While the class of compounds described in the article
are significantly different from the ones to which NC 381 belongs, they all form
part of the CLT library of analogues, which provide an opportunity to further
advance these analogues with the goal of developing novel anticancer
therapeutics. The results appear in an article entitled, "Triaryl-Methane
Derivatives as Antiproliferative Agents," published in a peer reviewed December
6th electronic version of the journal Bioorganic and Medicinal Chemistry
letters. The article will also be published in print in an upcoming issue of the
journal.
"These studies present promising results which we believe demonstrate that in
addition to NC 381, there are a number of other derivatives of CLT in the
library that are potential drug candidates. On September 24, 2003 Lorus
announced an agreement to out-license NC 381 and the library of CLT analogs."
said Dr. Jim Wright, CEO of Lorus.
About Lorus
Lorus is a biopharmaceutical company focused on the research and development of
cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical,
clinical and regulatory expertise by developing new drug candidates that can be
used, either alone, or in combination, to successfully manage cancer. Through
its own discovery efforts and an active acquisition and in-licensing program,
Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical
developments and marketing will be done in cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on the
OTC BB exchange under the symbol LORFF.
{PAGE}
Forward Looking Statements
Except for historical information, this press release contains forward-looking
statements, which reflect the Company's current expectation and assumptions, and
are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated. These forward-looking
statements involve risks and uncertainties, including, but not limited to,
changing market conditions, the Company's ability to obtain patent protection
and protect its intellectual property rights, commercialization limitations
imposed by intellectual property rights owned or controlled by third parties,
intellectual property liability rights and liability claims asserted against the
Company, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, product development delays, the Company's ability to attract
and retain business partners and key personnel, future levels of government
funding, the Company's ability to obtain the capital required for research,
operations and marketing and other risks detailed from time-to-time in the
Company's ongoing quarterly filings, annual information form, annual reports and
20-F filings. We undertake no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's
Internet site: http://www.lorusthera.com.
-30-
{/TEXT}
{/DOCUMENT}
279428
|
Lorus
As referenced in this Lorus Therapeutics Inc. Publishes Results of Synthesis and Characterization of Clotrimazole Analogues as Anticancer Agents:
LORUS THERAPEUTICS – TYPE}EX-99.2
{SEQUENCE}4
{FILENAME}t12179exv99w2.txt
{DESCRIPTION}EX-99.2
{TEXT}
{PAGE}
.
.
.
Exhibit 99.2
CONTACTS:
{TABLE}
{S} {C} {C}
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416)
_____________
LORUS THERAPEUTICS – ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
{/TABLE}
LORUS THERAPEUTICS INC. PUBLISHES RESULTS OF SYNTHESIS AND
CHARACTERIZATION OF CLOTRIMAZOLE ANALOGUES AS ANTICANCER AGENTS
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, DECEMBER 15, 2003 -
_____________
Lorus Therapeutics – RESULTS OF SYNTHESIS AND
CHARACTERIZATION OF CLOTRIMAZOLE ANALOGUES AS ANTICANCER AGENTS
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, DECEMBER 15, 2003 - Scientists at Lorus Therapeutics Inc.
("Lorus") have published the results of experimental studies aimed at
synthesizing and optimizing analogues of clotrimazole (CLT), an anti-fungal drug
that
_____________
Lorus Therapeutics – portfolio of promising anticancer drugs. Late-stage clinical
developments and marketing will be done in cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on the
OTC BB exchange under the
_____________
Lorus Therapeutics – undertake no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's
Internet site: http://www.lorusthera.com.
-30-
{/TEXT}
{/DOCUMENT}
_____________
dt 211244
| |
| Full Doc
| 2004 |
Lorus Announces Initiation of Phase II Clinical Program for Gti-2501 With Docetaxel in Hormone Refractory Prostate Cancer
Lorus Announces Initiation of Phase II Clinical Program for Gti-2501 With Docetaxel in Hormone Refractory Prostate Cancer (5K)
Doc #279429: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99.3
{SEQUENCE}5
{FILENAME}t12179exv99w3.txt
{DESCRIPTION}EX-99.3
{TEXT}
{PAGE}
.
.
.
Exhibit 99.3
CONTACTS:
{TABLE}
{S} {C} {C}
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
{/TABLE}
LORUS ANNOUNCES INITIATION OF PHASE II CLINICAL PROGRAM FOR GTI-2501
WITH DOCETAXEL IN HORMONE REFRACTORY PROSTATE CANCER
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, DECEMBER 23, 2003 - Lorus Therapeutics announced today that the
clinical study for GTI-2501for the treatment of hormone refractory prostate
cancer has been initiated at the Toronto Sunnybrook Regional Cancer Centre.
GTI-2501 will be administered in combination with docetaxel. The principal
investigator for this study is Dr. Scott Berry, and the co-investigator is Dr.
Laurence Klotz. Both clinicians are considered to be leaders in prostate cancer
research.
This collaboration between a leading Ontario research centre and an
Ontario-based innovative biopharmaceutical company is consistent with provincial
and federal policy to encourage novel clinical development in Canada. This marks
the first clinical trial of GTI-2501 in Canada, following the successful
conclusion of a Phase I clinical trial this year in the US.
GTI-2501 is an antisense drug that specifically targets the R1 component of
ribonucleotide reductase, which is required for DNA synthesis and cell division.
GTI-2501 has also shown marked antitumor activity in a wide variety of
preclinical cancer models, including prostate cancer.
This clinical trial will investigate the safety and efficacy of GTI-2501 in
combination with docetaxel, an active chemotherapy in hormone refractory
prostate cancer.
According to the Canadian Cancer Society and National Cancer Institute of Canada
statistics, prostate cancer is second only to lung cancer in the number of
deaths among men in Canada, about 4,300 deaths per year, and is the most
prevalent cancer in men. Once advanced prostate cancer stops responding to
hormonal therapies, treatment options are limited so the development of new
treatments is essential.
(more)
{PAGE}
"We are very pleased to be expanding our clinical program for GTI-2501 to a
major Canadian clinical research institution," said Dr Jim Wright, CEO of Lorus
Therapeutics. "Maintaining quality of life is a key concern when treating
prostate cancer. Based on preclinical and early human studies with GTI-2501, we
believe that it will be well tolerated as a combination chemotherapy with
potential for clinical efficacy in this challenging disease."
About Lorus
Lorus is a biopharmaceutical company focused on the research and development of
cancer therapies. Lorus' goal is to capitalize on its research, preclinical,
clinical and regulatory expertise by developing new drug candidates that can be
used, either alone, or in combination, to successfully manage cancer. Through
its own discovery efforts and an active acquisition and in-licensing program,
Lorus is building a portfolio of promising anti-cancer drugs. Late-stage
clinical developments and marketing will be done in cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on the
OTC BB exchange under the symbol LORFF.
Forward Looking Statements
Except for historical information, this press release contains forward-looking
statements, which reflect the Company's current expectation and assumptions, and
are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated. These forward-looking
statements involve risks and uncertainties, including, but not limited to,
changing market conditions, the Company's ability to obtain patent protection
and protect its intellectual property rights, commercialization limitations
imposed by intellectual property rights owned or controlled by third parties,
intellectual property liability rights and liability claims asserted against the
Company, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, product development delays, the Company's ability to attract
and retain business partners and key personnel, future levels of government
funding, the Company's ability to obtain the capital required for research,
operations and marketing and other risks detailed from time-to-time in the
Company's ongoing quarterly filings, annual information form, annual reports and
20-F filings. We undertake no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's
Internet site: http://www.lorusthera.com.
-30-
{/TEXT}
{/DOCUMENT}
279429
|
Lorus
As referenced in this Lorus Announces Initiation of Phase II Clinical Program for Gti-2501 With Docetaxel in Hormone Refractory Prostate Cancer:
LORUS THERAPEUTICS – TYPE}EX-99.3
{SEQUENCE}5
{FILENAME}t12179exv99w3.txt
{DESCRIPTION}EX-99.3
{TEXT}
{PAGE}
.
.
.
Exhibit 99.3
CONTACTS:
{TABLE}
{S} {C} {C}
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416)
_____________
Lorus Therapeutics – II CLINICAL PROGRAM FOR GTI-2501
WITH DOCETAXEL IN HORMONE REFRACTORY PROSTATE CANCER
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, DECEMBER 23, 2003 - Lorus Therapeutics announced today that the
clinical study for GTI-2501for the treatment of hormone refractory prostate
cancer has been initiated at the Toronto Sunnybrook
_____________
Lorus
Therapeutics. – pleased to be expanding our clinical program for GTI-2501 to a
major Canadian clinical research institution," said Dr Jim Wright, CEO of Lorus
Therapeutics. "Maintaining quality of life is a key concern when treating
prostate cancer. Based on preclinical and early human studies with GTI-2501,
_____________
Lorus Therapeutics – of promising anti-cancer drugs. Late-stage
clinical developments and marketing will be done in cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on the
OTC BB exchange under the
_____________
Lorus Therapeutics – undertake no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's
Internet site: http://www.lorusthera.com.
-30-
{/TEXT}
{/DOCUMENT}
_____________
dt 211245
| |
| Full Doc
| 2004 |
Lorus Therapeutics Inc. to Present Results of Virulizin(R) Mechanism Studies at the Asco Gastrointesitinal Cancers Symposium
Lorus Therapeutics Inc. to Present Results of Virulizin(R) Mechanism Studies at the Asco Gastrointesitinal Cancers Symposium (6K)
Doc #279431: This document is immediately available for purchase, but does not have a preview available for viewing.
{DOCUMENT}
{TYPE}EX-99.5
{SEQUENCE}7
{FILENAME}t12179exv99w5.txt
{DESCRIPTION}EX-99.5
{TEXT}
{PAGE}
.
.
.
Exhibit 99.5
CONTACTS:
{TABLE}
{S} {C} {C}
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Inc. Grace Tse Mansfield Communications Inc. Mansfield Communications
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
{/TABLE}
LORUS THERAPEUTICS INC. TO PRESENT RESULTS OF VIRULIZIN(R) MECHANISM
STUDIES AT THE ASCO GASTROINTESITINAL CANCERS SYMPOSIUM
-Latest research into Virulizin(R) as an antitumor agent to be presented -
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, JANUARY 22, 2003 - Lorus Therapeutics Inc. ("Lorus") will be
attending the American Society of Clinical Oncology (ASCO) Gastrointestinal
Cancers Symposium to be held in San Francisco on January 22-24, 2004. An
abstract entitled, "Induction of NK cell and macrophage infiltration into tumors
may contribute to antitumor activity of Virulizin(R)," has been accepted for
presentation. The abstract will also be published in the meeting proceedings.
These studies were conducted as a collaboration between Lorus scientists and
researchers at the Calcium Research Laboratory, Department of Medicine, McGill
University.
Virulizin(R) has demonstrated antitumor activity against a variety of tumors
including pancreatic cancer and melanoma. A significant role for an immune-based
mechanism of action has been described in this presentation and an earlier study
had shown that macrophages, cells involved in innate immunity, are involved in
Virulizin(R)-mediated antitumor activity. This presentation will summarize the
latest research with animal models into the antitumor mechanism of action of
Virulizin(R).
The present study extends the previous findings and identifies natural killer
(NK) cells as participants in Virulizin(R)'s mechanism of action. NK cells
constitute another major cellular component of the innate immune system and are
essential to early surveillance and removal of cancer cells.
(more)
{PAGE}
Virulizin(R) treatment of mice bearing human tumors resulted in increased
numbers of both macrophages and NK cells within the implanted tumors. Time
course experiments demonstrated that recruitment of these cells to tumors was
rapid after initiation of Virulizin(R) treatment, and correlated with early
signs of programmed cell death. In mice with NK cell-deficiency, the antitumor
activity of Virulizin(R) was greatly reduced. In addition, depletion of
macrophages from mice resulted in the loss of the Virulizin(R)-induced increase
in NK cells in tumors.
Taken together, these data support a mechanism in which Virulizin(R) induces a
rapid and sustained induction of the innate cellular immune system resulting in
antitumor activity based on the interplay between macrophages and NK cells.
"The research team at Lorus continues to build upon previous observations and
the data being presented are an indication of our deepened understanding of the
mechanism by which Virulizin(R) acts as an anticancer agent," said Dr. Jim
Wright, chief executive officer of Lorus.
About Lorus
Lorus is a biopharmaceutical company focused on the research and development of
cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical,
clinical and regulatory expertise by developing new drug candidates that can be
used, either alone, or in combination, to successfully manage cancer. Through
its own discovery efforts and an acquisition and in-licensing program, Lorus is
building a portfolio of promising anticancer drugs. Late-stage clinical
developments and marketing may be done in cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on the
OTC BB exchange under the symbol LORFF.
Forward Looking Statements
Except for historical information, this press release contains forward-looking
statements, which reflect the Company's current expectation and assumptions, and
are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated. These forward-looking
statements involve risks and uncertainties, including, but not limited to,
changing market conditions, the Company's ability to obtain patent protection
and protect its intellectual property rights, commercialization limitations
imposed by intellectual property rights owned or controlled by third parties,
intellectual property liability rights and liability claims asserted against the
Company, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, product development delays, the Company's ability to attract
and retain business partners and key personnel, future levels of government
funding, the Company's ability to obtain the capital required for research,
operations and marketing and other risks detailed from time-to-time in the
Company's ongoing quarterly filings, annual information form, annual reports and
20-F filings. We undertake no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's
Internet site: http://www.lorusthera.com.
-30-
{/TEXT}
{/DOCUMENT}
279431
|
Lorus
As referenced in this Lorus Therapeutics Inc. to Present Results of Virulizin(R) Mechanism Studies at the Asco Gastrointesitinal Cancers Symposium:
LORUS THERAPEUTICS – TYPE}EX-99.5
{SEQUENCE}7
{FILENAME}t12179exv99w5.txt
{DESCRIPTION}EX-99.5
{TEXT}
{PAGE}
.
.
.
Exhibit 99.5
CONTACTS:
{TABLE}
{S} {C} {C}
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Inc. Grace Tse Mansfield Communications Inc. Mansfield Communications
Tel: (416)
_____________
LORUS THERAPEUTICS – ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
{/TABLE}
LORUS THERAPEUTICS INC. TO PRESENT RESULTS OF VIRULIZIN(R) MECHANISM
STUDIES AT THE ASCO GASTROINTESITINAL CANCERS SYMPOSIUM
-Latest research into Virulizin(R) as an antitumor
_____________
Lorus Therapeutics – SYMPOSIUM
-Latest research into Virulizin(R) as an antitumor agent to be presented -
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, JANUARY 22, 2003 - Lorus Therapeutics Inc. ("Lorus") will be
attending the American Society of Clinical Oncology (ASCO) Gastrointestinal
Cancers Symposium to be held in San Francisco on January
_____________
Lorus Therapeutics – portfolio of promising anticancer drugs. Late-stage clinical
developments and marketing may be done in cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on the
OTC BB exchange under the
_____________
Lorus Therapeutics – undertake no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's
Internet site: http://www.lorusthera.com.
-30-
{/TEXT}
{/DOCUMENT}
_____________
dt 211247
| |
Preview
Full Doc
| 2004 |
Neoprobe Announces First Quarter Results Provides Business Update
Neoprobe Announces First Quarter Results Provides Business Update (18K)
Doc #282394: Click preview link for longer preview.
IMMEDIATE RELEASE MAY 12, 2004
CONTACTS:
BRENT LARSON JONATHAN FASSBERG,
VICE PRESIDENT / CFO THE TROUT GROUP
614 793 7500 212 477 9007
-----------------------------------------------------------------------------
NEOPROBE ANNOUNCES FIRST QUARTER RESULTS
PROVIDES BUSINESS UPDATE
DUBLIN, OHIO - May 12, 2003 -- Neoprobe Corporation (OTCBB: NEOP), a diversified
developer of innovative oncology and cardiovascular surgical and diagnostic
products, today announced consolidated operating results for the first quarter
of 2004. First quarter results included revenues of $1.4 million compared to
$1.5 million for the first quarter of 2003. In addition, Neoprobe reported a net
loss of $589,000 or $0.01 per share compared to a loss of $479,000 or $0.01 per
share for the comparable period in 2003. Total operating expenses were $1.4
million for the first quarter of 2004 compared to $1.2 million for the first
quarter of 2003.
David Bupp, Neoprobe's President & CEO said, "Our first quarter revenue was
impacted by delays in the transfer of manufacturing of our neo2000(R) gamma
detection device to our new contract manufacturer that resulted in our
accumulating backorders to our primary distributor of over $125,000 at March 31.
If we had not been in a backorder position, which has since been corrected, our
gamma device revenue would have been consistent with last year as expected. In
addition, recent design improvements to the neo2000 have already contributed to
an increase in gross margins on device sales to 56% of net sales compared to 36%
of net sales in the prior year."
"Revenue from our blood flow line has been lower than planned so far this year,"
Bupp continued. "The feedback we are receiving from clinicians following
marketing clearance of our lead blood flow product, the Quantix/OR(TM), has been
gratifying. These early clinical exposures have also brought suggestions for
product enhancements that we believe will stimulate a demand from blood flow
measurement practitioners and expand our market by attracting surgeons not
presently using blood flow measurement technology. We have already initiated
efforts to implement the improvements to respond to the suggestions, the first
of which will be completed during the second quarter. The Quantix/OR has gained
attention in the last four months through two major cardiovascular and vascular
tradeshows and we have now completed training seven vascular-specific
professional distributor sales teams covering 20 states in the U.S. We are
working with additional sales teams that cover an incremental 13 states and are
identifying additional representatives to cover the remaining states. We are
particularly encouraged by the willingness of North American and European
thought leaders to continue their evaluation of the product as these exciting
product improvements are implemented."
Operating expenses during the quarter increased over the prior year due
282394
| |
UCSD
As referenced in this Neoprobe Announces First Quarter Results Provides Business Update:
University of
California, San Diego – including
Lymphoseek(TM) and RIGScan(R) CR49. Lymphoseek is an investigational drug being
developed as a lymphatic tracing agent in conjunction with the University of
California, San Diego . The RIGS(R) system is an investigational technology that
combines the Company's gamma detection device technology with a proprietary
disease-specific
_____________
dt 217453
|
| Full Doc
| 2004 |
Diversity of Customer Base December 31, 2003 Enrollment
Diversity of Customer Base December 31, 2003 Enrollment (1K)
Doc #299926: This document is immediately available for purchase, but does not have a preview available for viewing.
WellPoint Health Networks Inc
EX-99.1 3 a04-1783_1ex99d1.htm EX-99.1
Exhibit 99.1 Diversity of Customer Base December 31, 2003 Enrollment5,932,000 Large Group ASO (includes 1.2 million network access members and 1.0 million BlueCard host members) 4,132,000 Large Group Insured 1,497,000 Individual 1,415,000 Small Group 845,000 Medi-Cal (California Medicaid program) 726,000 Other State Sponsored Programs 464,000 Seniors Specialty Products For the year ended December 31, 2002, net income for the Companys Specialty segment composed 13% and net income for the Companys Health Care segment composed 87% of the Companys net income for the Companys Health Care and Specialty segments combined. For the year ended December 31, 2003, net income for the Companys Specialty segment composed 14% and net income for the Companys Health Care segment composed 86% of the Companys net income for the Companys Health Care and Specialty segments combined. From the year ended December 31, 2002 to the year ended December 31, 2003, net income for the Companys Health Care segment grew 40% and net income for the Companys Specialty segment grew 55%.
299926
| | |
| Full Doc
| 2004 |
Anthem Reports Record Results for the First Quarter 2004
Anthem Reports Record Results for the First Quarter 2004 (21K)
Doc #301136: This document is immediately available for purchase, but does not have a preview available for viewing.
news release
Anthem, Inc.
120 Monument Circle
Indianapolis, IN 46204
Tel 317 488-6390
Fax 317 488-6460
Anthem Reports Record Results for the First Quarter 2004
?
Enrollment increased 592,000 members, or 5 percent over December 2003
?
Earnings of $2.08 per share increased 53 percent over the first quarter of 2003
?
Expectations for 2004 increased to a range of $6.90 to $7.00 per share
Indianapolis, IN ? April 28, 2004 ? Anthem, . . .
301136
|
Anthem
As referenced in this Anthem Reports Record Results for the First Quarter 2004:
Anthem, Inc –
Press Release
EX-99 2 dex99.htm PRESS RELEASE
Exhibit 99
news release
Anthem, Inc .
120 Monument Circle
Indianapolis, IN 46204
Tel 317 488-6390
Fax 317 488-6460
Anthem Reports Record Results for the First Quarter
_____________
Anthem, Inc – quarter of 2003
Expectations for 2004 increased to a range of $6.90 to $7.00 per share
Indianapolis, IN April 28, 2004 Anthem, Inc . (NYSE: ATH) today announced first quarter 2004 net income increased to $295.6 million, or $2.08 per share, compared with net
_____________
Anthem, Inc – leading brand, and appreciate our consistent focus on providing distinctive customer service, said Larry C. Glasscock, chairman, president and chief executive officer of Anthem, Inc . Record levels of revenue and discipline in managing administrative expenses over a larger membership base contributed to our strong results in the
_____________
Anthem, Inc – 4 days as of December 31, 2003. The decline was primarily driven by further reduction in the time between service and claim payment.
Anthem, Inc .
Operating Segment Highlights - First Quarter 2004
($ in Millions)
Three Months Ended
March 31
2004
2003
Change
Operating Revenue:
Midwest
$
1,856.0
$
_____________
Anthem, Inc – Investor Relations
Media
Tami Durle, 317-488-6390
Ed West, 317-488-6100
tami.durle@anthem.com
edward.west@anthem.com
About Anthem
Anthem, Inc . is an Indiana-domiciled publicly traded company that, through its subsidiary companies, provides health care benefits to more than 12.5 million
_____________
dt 266946
;
|
WellPoint Health
As referenced in this Anthem Reports Record Results for the First Quarter 2004:
WellPoint Health Networks Inc – litigation targeted at health benefits companies; our ability to contract with providers consistent with past practice; our ability to consummate Anthems merger with WellPoint Health Networks Inc ., to achieve expected synergies and operating efficiencies in the merger within the expected time-frames or at all and to successfully integrate
_____________
WellPoint Health Networks Inc – WHERE TO FIND IT
This press release may be deemed to be solicitation material in respect of the proposed merger of Anthem and WellPoint Health Networks Inc . (WellPoint). Anthem has filed on November 26, 2003 a preliminary registration statement on Form S-4, including the preliminary joint proxy statement/
_____________
dt 272378
|
| Full Doc
| 2003 |
Crown Cork & Seal Completes $3.2 Billion Refinancing And Forms Crown Holdings, Inc. as a New Public Holding Company
Crown Cork & Seal Completes $3.2 Billion Refinancing And Forms Crown Holdings, Inc. as a New Public Holding Company (4K)
Doc #205391: This document is immediately available for purchase, but does not have a preview available for viewing.
Crown Cork & Seal Co Inc
Press Release
EX-99.1 5 dex991.htm PRESS RELEASE
Exhibit 99.1
CROWN CORK & SEAL COMPLETES $3.2 BILLION REFINANCING
AND FORMS CROWN HOLDINGS, INC. AS A NEW PUBLIC HOLDING COMPANY
Philadelphia, PA February 26, 2003. Crown Cork & Seal Company, Inc. (NYSE: CCK), announced today that it has completed its previously announced comprehensive refinancing plan and formed a new public holding company. The $3.2 billion refinancing consists of the sale of $1.085 billion of 9- 1/2% second priority senior secured notes due 2011, 285 million of 10- 1/4% second priority senior secured notes due 2011 and $725 million of 10- 7/8% third priority senior secured notes due 2013; and a new $550 million first priority revolving credit facility due in 2006 and a first priority term loan due in 2008 consisting of $450 million and 50 million. The proceeds from the refinancing plan are being used to refinance Crown Cork & Seals prior revolving credit facility and certain of the Companys existing unsecured senior notes as well as to pay fees and expenses associated with the refinancing.
John W. Conway, Chief Executive Officer of Crown, commented: We are very pleased with the refinancing plan and the confidence shown in Crown by investors. The refinancing improves our liquidity and, extends the maturities of most of our debt to 2006 and beyond. We are now able to focus all of our attention on strengthening Crowns leadership position in its core businesses.
In conjunction with the refinancing plan, the Company formed a new public holding company named Crown Holdings, Inc., a Pennsylvania corporation. Crown Cork & Seal Company, Inc. is now a wholly owned subsidiary of Crown Holdings. As a result, shareholders of Crown Cork & Seal became shareholders of Crown Holdings and have the same number of shares and percentage ownership and the same rights, privileges and interests with respect to Crown Holdings that they held in Crown Cork & Seal immediately prior to the reorganization.
The conversion of shares of Crown Cork & Seal into shares of Crown Holdings occurred without the physical exchange of certificates, and certificates formerly representing shares of Crown Cork & Seal are deemed to represent shares of Crown Holdings. The holding company reorganization is tax free to shareholders.
The common stock of Crown Holdings will continue to be publicly traded under the symbol CCK on the New York Stock Exchange.
The senior secured notes were issued in a private placement and resold by the initial purchasers to qualified institutional buyers under Rule 144A of the Securities Act of 1933. The senior secured notes have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security in any jurisdiction in which such offer or sale would be unlawful. Additional information regarding the refinancing and formation of the new holding company can be obtained in Company SEC filings.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all other information in this press release consists of forward-looking statements. These forward-looking statements involve a number of risks, uncertainties and other factors that may cause actual results to be materially different from those expressed or implied in the forward-looking statements. Important factors that could cause the statements made in this press release to differ include that the final application of proceeds and the effects of the refinancing plan could vary. Other important factors are discussed under the caption Forward-Looking Statements in the Companys Form 10-K Annual Report for the year ended December 31, 2001 and in subsequent filings. The Company does not intend to review or revise any particular forward-looking statement in light of future events.
Crown Cork & Seal is a leading supplier of packaging products to consumer marketing companies around the world. World headquarters are located in Philadelphia, Pennsylvania.
For more information, contact:
Timothy J. Donahue, Senior Vice President-Finance, (215) 698-5088
Edward Bisno, Edelman Financial, (212) 704-8212
205391
| |
Crown Holdings
As referenced in this Crown Cork & Seal Completes $3.2 Billion Refinancing And Forms Crown Holdings, Inc. as a New Public Holding Company:
CROWN HOLDINGS, – RELEASE
Exhibit 99.1
CROWN CORK & SEAL COMPLETES $3.2 BILLION REFINANCING
AND FORMS CROWN HOLDINGS, INC. AS A NEW PUBLIC HOLDING COMPANY
Philadelphia, PA February 26, 2003. Crown Cork &
Crown Holdings, – In conjunction with the refinancing plan, the Company formed a new public holding company named Crown Holdings, Inc., a Pennsylvania corporation. Crown Cork & Seal Company, Inc. is now a wholly
Crown Holdings. – Pennsylvania corporation. Crown Cork & Seal Company, Inc. is now a wholly owned subsidiary of Crown Holdings. As a result, shareholders of Crown Cork & Seal became shareholders of Crown Holdings
Crown Holdings – of Crown Holdings. As a result, shareholders of Crown Cork & Seal became shareholders of Crown Holdings and have the same number of shares and percentage ownership and the same rights, privileges
Crown Holdings – of shares and percentage ownership and the same rights, privileges and interests with respect to Crown Holdings that they held in Crown Cork & Seal immediately prior to the reorganization.
The conversion
dt 25677
|
| Full Doc
| 2003 |
Crown Cork & Seal Announces Concurrent Tender Offers for Any and All Outstanding Notes of Certain Of Its Series of Notes Maturing Prior to 2006
Crown Cork & Seal Announces Concurrent Tender Offers for Any and All Outstanding Notes of Certain Of Its Series of Notes Maturing Prior to 2006 (3K)
Doc #205399: This document is immediately available for purchase, but does not have a preview available for viewing.
CROWN CORK & SEAL ANNOUNCES CONCURRENT TENDER
OFFERS FOR ANY AND ALL OUTSTANDING NOTES OF CERTAIN
OF ITS SERIES OF NOTES MATURING PRIOR TO 2006
Philadelphia, PA ? February 4, 2003. Crown Cork & Seal Company, Inc. (NYSE: CCK), announced today that it has commenced concurrent tender offers for any and all of the outstanding notes of the Company and its subsidiaries described in the table below. The tender offers comprise part of the Company?s recently announced comprehensive refinancing plan.
The series of . . .
205399
|
Mellon Investor
As referenced in this Crown Cork & Seal Announces Concurrent Tender Offers for Any and All Outstanding Notes of Certain Of Its Series of Notes Maturing Prior to 2006:
Mellon Investor Services – is acting as Dealer Manager for the tender offers. The Information Agent and Depositary is Mellon Investor Services LLC.
This press release is neither an offer to purchase nor a solicitation of an
Mellon Investor Services – the Offer to Purchase dated February 4, 2003. Requests for information should be directed to Mellon Investor Services at (800) 903-7594. Questions regarding the tender offers should be directed to Salomon Smith
dt 41299
;
|
Salomon
As referenced in this Crown Cork & Seal Announces Concurrent Tender Offers for Any and All Outstanding Notes of Certain Of Its Series of Notes Maturing Prior to 2006:
Salomon Smith Barney – condition that the Companys refinancing plan is consummated on terms satisfactory to the Company. Each tender offer is made independently of the other.
Salomon Smith Barney Inc. is acting as Dealer Manager for the tender offers. The Information Agent and Depositary is Mellon Investor Services LLC.
This press release
_____________
Salomon Smith Barney – Requests for information should be directed to Mellon Investor Services at (800) 903-7594. Questions regarding the tender offers should be directed to Salomon Smith Barney Inc. at (800) 558-3745 or collect at (212) 723-6106.
Crown Cork & Seal is a leading supplier of packaging products to consumer
_____________
dt 87640
;
Smith Barney
As referenced in this Crown Cork & Seal Announces Concurrent Tender Offers for Any and All Outstanding Notes of Certain Of Its Series of Notes Maturing Prior to 2006:
Smith Barney Inc – that the Companys refinancing plan is consummated on terms satisfactory to the Company. Each tender offer is made independently of the other.
Salomon Smith Barney Inc . is acting as Dealer Manager for the tender offers. The Information Agent and Depositary is Mellon Investor Services LLC.
This press release
_____________
Smith Barney Inc – for information should be directed to Mellon Investor Services at (800) 903-7594. Questions regarding the tender offers should be directed to Salomon Smith Barney Inc . at (800) 558-3745 or collect at (212) 723-6106.
Crown Cork & Seal is a leading supplier of packaging products to consumer
_____________
dt 142917
|
| Full Doc
| 2003 |
Crown Cork & Seal Reports 2002 Fourth Quarter And Year End Results Comprehensive Refinancing Plan Announced
Crown Cork & Seal Reports 2002 Fourth Quarter And Year End Results Comprehensive Refinancing Plan Announced (20K)
Doc #205401: This document is immediately available for purchase, but does not have a preview available for viewing.
News Release
Crown Cork & Seal Company, Inc.
Corporate Headquarters
One Crown Way
Philadelphia, PA 19154-4599
CROWN CORK & SEAL REPORTS 2002 FOURTH QUARTER
AND YEAR END RESULTS
COMPREHENSIVE REFINANCING PLAN ANNOUNCED
Philadelphia, PA?January 29, 2003. Crown Cork & Seal Company, Inc. (NYSE: CCK), announced today its results for the fourth quarter and year ended December 31, 2002, as well as a comprehensive refinancing plan.
For the fourth quarter of 2002, the Company reported a . . .
205401
|
Citicorp
As referenced in this Crown Cork & Seal Reports 2002 Fourth Quarter And Year End Results Comprehensive Refinancing Plan Announced:
Citicorp North America, – stated maturities in 2006 and beyond. The plan, which is currently under discussion with financing sources and rating agencies, includes a commitment by Citicorp North America, Inc. and Deutsche Bank Trust Company Americas to provide the $550 million first lien revolving credit facility.
The refinancing plan is currently
_____________
Citicorp North America, – placement and resold by the initial purchasers to qualified institutional buyers under Rule 144A of the Securities Act of 1933. The commitments of Citicorp North America, Inc. and Deutsche Bank Trust Company Americas are subject to certain conditions, including the completion of the other components of the financing.
_____________
dt 158253
;
Constar Int'l
As referenced in this Crown Cork & Seal Reports 2002 Fourth Quarter And Year End Results Comprehensive Refinancing Plan Announced:
Constar International – As previously announced, the Company completed the sale of 89.5% of its interest in Constar International during the fourth quarter. The Company recorded a net loss of $213 million on the
dt 25561
;
|
DB Trust
As referenced in this Crown Cork & Seal Reports 2002 Fourth Quarter And Year End Results Comprehensive Refinancing Plan Announced:
Deutsche Bank Trust Co – beyond. The plan, which is currently under discussion with financing sources and rating agencies, includes a commitment by Citicorp North America, Inc. and Deutsche Bank Trust Co mpany Americas to provide the $550 million first lien revolving credit facility.
The refinancing plan is currently contemplated to be completed by the
_____________
Deutsche Bank Trust Co – initial purchasers to qualified institutional buyers under Rule 144A of the Securities Act of 1933. The commitments of Citicorp North America, Inc. and Deutsche Bank Trust Co mpany Americas are subject to certain conditions, including the completion of the other components of the financing. The final terms of the senior
_____________
dt 113908
|
| Full Doc
| 2003 |
Kaiser Aluminum Reluctantly Agrees to Termination of Salaried Employees Retirement Plan
Kaiser Aluminum Reluctantly Agrees to Termination of Salaried Employees Retirement Plan (2K)
Doc #232819: This document is immediately available for purchase, but does not have a preview available for viewing.
Exhibit 99.1
For information: Scott Lamb
Telephone: (713) 332-4751 December 19, 2003
KAISER ALUMINUM RELUCTANTLY AGREES TO TERMINATION OF SALARIED EMPLOYEES
RETIREMENT PLAN
HOUSTON, Texas, December 19, 2003 -- Kaiser Aluminum said that it has been
notified by the Pension Benefit Guaranty Corporation (PBGC) that the PBGC
intends to assume responsibility for the Kaiser Aluminum Salaried Employees
Retirement Plan (KRP) as of December 17, 2003. After appropriate consultation
with its advisors, the Unsecured Creditors' Committee, the Asbestos Claimants
Committee, and certain other constituents, the company has reluctantly agreed to
the termination of the plan.
The Company has stated since the inception of its Chapter 11
reorganization proceedings that pension obligations were one of the significant
legacy factors that would have to be addressed during the reorganization
process. Further, the Company has stated that it did not expect to make any
pension contributions in respect of its domestic pension plans during the
pendency of the cases because it believes that virtually all of such amounts are
pre-petition obligations. In addition, the company also has previously stated
that termination of the pension plans was a possibility.
The PBGC action does not address seven other defined benefit plans
sponsored by the Company and thus does not resolve all the pertinent issues
surrounding the Company's material pension obligations. As previously disclosed,
the Company is discussing modification or termination of hourly retiree benefits
pursuant to collective bargaining with the appropriate union representatives.
Kaiser Aluminum (OTCBB: KLUCQ) is a leading producer of fabricated
aluminum products, alumina, and primary aluminum.
F-965
Company press releases may contain statements that constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. The company cautions that any such forward-looking statements are not
guarantees of future performance and involve significant risks and
uncertainties, and that actual results may vary materially from those expressed
or implied in the forward-looking statements as a result of various factors.
232819
| | |
| Full Doc
| 2003 |
Kaiser Aluminum Credit Agreement Amendment Becomes Effective
Kaiser Aluminum Credit Agreement Amendment Becomes Effective (1K)
Doc #232826: This document is immediately available for purchase, but does not have a preview available for viewing.
Exhibit 99.1
For information: Scott Lamb
Telephone: (713) 332-4751 August 20, 2003
KAISER ALUMINUM CREDIT AGREEMENT AMENDMENT BECOMES
EFFECTIVE
HOUSTON, Texas, August 20, 2003 -- Kaiser Aluminum said the previously
disclosed sixth amendment to its existing Credit Agreement has become effective.
The sixth amendment increases availability by approximately $45 million
and extends the term of the Credit Agreement by one year, to February 2005.
Although Kaiser is targeting emergence from Chapter 11 in 2004, the company had
sought a full one-year extension of the Credit Agreement, in part, to provide
customers and suppliers with assurance that financing is committed well into the
future.
Kaiser Aluminum Corporation (OTCBB:KLUCQ) is a leading producer of
fabricated aluminum products, alumina, and primary aluminum.
F-958
Company press releases may contain statements that constitute
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. The company cautions that any such
forward-looking statements are not guarantees of future results and involve
significant risks and uncertainties, and that actual results may vary materially
from those expressed or implied in the forward-looking statements as a result of
various factors.
|